CDK4 and neuroblastoma: We conclude that treatment of the neuroblastoma cell line SK-N-BE(2)C with any CDK4/6 inhibitor (palbociclib, abemaciclib or ribociclib) at IC50 concentrations results in RB hypo-phosphorylation and both reduces proliferation and induces differentiation, without extensive cell death.